Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y., . . . Weller, M. (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. The lancet. Oncology, 15(10), . https://doi.org/10.1016/S1470-2045(14)70379-1
Chicago-Zitierstil (17. Ausg.)Stupp, Roger, et al. "Cilengitide Combined with Standard Treatment for Patients with Newly Diagnosed Glioblastoma with Methylated MGMT Promoter (CENTRIC EORTC 26071-22072 Study): A Multicentre, Randomised, Open-label, Phase 3 Trial." The Lancet. Oncology 15, no. 10 (2014). https://doi.org/10.1016/S1470-2045(14)70379-1.
MLA-Zitierstil (9. Ausg.)Stupp, Roger, et al. "Cilengitide Combined with Standard Treatment for Patients with Newly Diagnosed Glioblastoma with Methylated MGMT Promoter (CENTRIC EORTC 26071-22072 Study): A Multicentre, Randomised, Open-label, Phase 3 Trial." The Lancet. Oncology, vol. 15, no. 10, 2014, https://doi.org/10.1016/S1470-2045(14)70379-1.